ReviewCardiac failure review2021
Cardiac Sarcoidosis: When and How to Treat Inflammation.
Review in Cardiac failure review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Diagnostic challenges in isolated cardiac sarcoidosis.ESC heart failure · 2026Review
- Granulomas in the Heart: Pathophysiology, Diagnosis, Management, and Outcomes in Cardiac Sarcoidosis.Cureus · 2026Review
- Cardiac sarcoidosis: The role of steroid therapy in managing myocardial inflammation and arrhythmic risks.World journal of cardiology · 2025Review
- Article
- A Rare Coexistence of Klippel-Trenaunay Syndrome and Cardiac Sarcoidosis.Biomedicines · 2025Article
- A Case Report: The Utility of Multimodality Imaging in the Diagnosis of Cardiac Sarcoidosis-Has It Surpassed the Need for a Biopsy?Reports (MDPI) · 2025Article
- Corticosteroid therapy and long-term outcomes in patients with cardiac sarcoidosis stratified by left ventricular ejection fraction.European heart journal open · 2025Article
- Innovations in Imaging:Current cardiology reports · 2024Review
- The Emerging Specialty of Cardio-Rheumatology.Current atherosclerosis reports · 2024Review
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024Review
- Cardiac sarcoidosis: diagnosis and management.Frontiers in cardiovascular medicine · 2024Review
- Great mimicker: definite isolated cardiac sarcoidosis masquerading as hypertrophic cardiomyopathy.BMJ case reports · 2023Article
- Typical trident sign and cardiac involvement in a patient suspected to Sarcoidosis despite negative whole-body FDG-PET: a case report.Journal of medical case reports · 2023Article
- Cardiac Sarcoidosis: A Literature Review of Current Recommendations on Diagnosis and Management.Cureus · 2023Review
- Sore, Hot, and at Risk: The Emerging Specialty of Cardio-Rheumatology.Journal of the American Heart Association · 2023Article
- Article
- Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application.Journal of cardiovascular development and disease · 2023Review
- Pragmatic electrocardiogram tracings in non-ischaemic dilated cardiomyopathy: diagnostic and prognostic role.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.European heart journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.